Study in obese mice ties tirzepatide's GIP receptor to insulin sensitivity without weight loss
Mouse research suggests tirzepatide can improve insulin sensitivity through the GIP receptor even without weight loss, a mechanism that has not been shown in people.
Researchers at Eli Lilly and Company report that tirzepatide improved insulin sensitivity in obese mice through the GIP receptor, and that the improvement occurred even though the animals lost no weight. The study was published May 18, 2021, in the Journal of Clinical Investigation [1].
Tirzepatide is the active molecule in Mounjaro and Zepbound. At the time of the study, it was being tested as a treatment that acts on two gut hormone receptors: GIP and GLP-1. Semaglutide, sold as Ozempic, Wegovy and Rybelsus, acts on the GLP-1 receptor [1].
The experiments used obese mice bred to lack the GLP-1 receptor. In those animals, tirzepatide increased the glucose infusion rate 1.7-fold [1]. The glucose infusion rate measures how much glucose is cleared from the bloodstream during a controlled infusion, and it is a standard way to gauge insulin sensitivity: the higher the rate, the more responsive the body is to insulin.
The mice did not lose weight during the study [1]. When the researchers followed where the glucose was going, they traced the effect to glucose disposal into white adipose tissue, the body's main fat storage tissue [1]. Because the animals could not respond to GLP-1 and did not lose weight, the authors concluded that GIP receptor agonism, the GIP side of tirzepatide's activity, was mediating the insulin-sensitizing effect [1].
The paper appears as a research article in the journal's metabolism section and is free to read, with the identifier 10.1172/JCI146353 [1]. The authors list Lilly Research Laboratories in Indianapolis, Indiana, as their affiliation [1].
Why it matters for patients
Blood sugar control and weight loss are usually discussed together for GLP-1 and dual-agonist drugs, and weight loss is often assumed to be the main reason glucose improves. This study points to a separate route in mice, one that works through the GIP receptor and does not depend on the animals getting thinner [1].
It is a mouse study, and that limits what it can say about people. The paper does not report any human data, so it does not establish that the same mechanism operates in patients, or how much of tirzepatide's effect on blood sugar in people comes from this pathway rather than from weight loss [1]. The experiments also were not designed to test dosing, and nothing in the paper addresses how the drug is prescribed [1].
For someone taking tirzepatide, semaglutide or a related medicine, the practical takeaway is narrow: this is early laboratory work on how one drug may act, not a finding that changes what is known about these medications in humans [1].
What happens next
The paper does not describe follow-up studies in people or give dates for future research [1]. Whether GIP receptor agonism produces measurable insulin sensitization in humans, independent of weight loss, has not been reported here. How the mouse findings might translate to human metabolism, and whether they would matter for blood sugar targets or treatment decisions, is not yet known [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.